Would you offer PMRT to a perimenopausal female with a single positive LN with microscopic ENE who has otherwise low risk features?

In this case, I would discuss the role of PMRT given her nodal involvement with microscopic ENE and being perimenopausal, despite having other low risk features. I would counsel the patient that the data suggests reductions in LRR with improvements in DFS, and DDFS though no clear survival advantage...

If low genomic score, I would favor no RT.